Renzapride

Revision as of 18:20, 27 September 2011 by WikiBot (talk | contribs) (Protected "Renzapride": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
File:Renzapride structure.png
Chemical structure of Renzapride

Renzapride is a full serotonin 5-HT4 receptor agonist, partial serotonin 5-HT3 receptor antagonist.

Clinical Uses

Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme of the UK.

Template:Pharma-stub